AEYE Diagnostic Screening
AEYE-DS utilizes Artificial Intelligence (AI) technology to instantly diagnose diabetic retinopathy from retinal images.
AEYE with TOPCON
First to be proven accurate on both a desktop camera and a portable handheld camera
AURORA AEYE
CAUTION: Federal (US) law restricts this device to investigational use only.
NOT SOLD IN THE US
Best-in-class Accuracy
Proven accurate in clinical trials on both desktop and handheld
Desktop
91.4%
Specificity
93.0%
Sensitivity
Handheld
93.6%
Specificity
91.9%
Sensitivity
The Only Practical Solution
The exam takes 1 minutes on average and rarely requires dilation
1 min
exam avg.
Instant
Diagnostic report
No
Dilation
Closes Care Gaps
Enables point-of-care screening instead of referring to a specialist
CPT 92229
Reimbursement Code
Measure 117
HEDIS Quality Measure
Over 35M
people with diabetes in the US and 422M worldwide are at risk of sight-threatening diabetic retinopathy.
85%
of people over 40 with diabetes will develop diabetic retinopathy.
Why it matters
Screening Prevents Blindness
Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.
Only 15% to 50%
of patients with diabetes in the US adhere to the recommended screening.
Closing care gaps
Replacing specialist screening with AI diagnosis
Using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap
Before
After
Benefits of
Point-of-Care Screening
Practical
Requires only one image per eye; rarely requires dilation
Accurate
Best-in-class efficacy proven in a pivotal prospective FDA study
Simple to operate
Screening, taking only one minutes on average, can be done by any healthcare staff
Reimbursable
Dedicated CPT code 92229
Closes Care Gaps
Closes the diabetic eye exam care gap for HEDIS/Star quality measures